Reboot Communications Ltd.’s Post

This #WorldMEDay we’re highlighting PrecisionLife and its Innovate UK #AdvancingPrecisionMedicine funded project to investigate the causes of myalgic encephalomyelitis (ME)/chronic fatigue syndrome (CFS) and #LongCovid ME/CFS and long Covid are debilitating conditions, profoundly affecting the quality of life and socioeconomic participation of over two million people in the UK. There are currently no effective ways to diagnose the conditions and no therapies that affect the diseases. PrecisionLife’s analytical platform recently identified the first reproducible genetic associations with ME/CFS and long Covid. Their Innovate UK funded project will extend this work to include analysis of a larger patient dataset from the world’s largest ME/CFS study, DecodeME, developed by the ME/CFS partnership between @ActionForME and the Human Genetics Unit at the @University-of-Edinburgh, as well as additional long Covid patients. Find out more about the project https://lnkd.in/eMbdE78j Find out more about the support available from Innovate UK https://lnkd.in/eZSgwK5G #MECFS #PrecisionMedicine #ResearchFunding

Advancing Equitable Genomic Testing for a Healthier Future The promise of genomic testing lies in its ability to revolutionize healthcare through personalized medicine. However, achieving equitable access to these advancements is paramount. Here are key considerations: 🔬 Diverse Representation in Research: Ensuring that genomic research includes diverse populations helps in understanding the genetic basis of diseases across different ethnic groups, leading to more effective treatments for all. 💡 Accessible Testing: Making genomic testing affordable and accessible to underserved communities is essential. This includes providing tests in various languages and ensuring they are covered by insurance. 🤝 Community Engagement: Building trust within communities through transparent communication and partnerships is vital. Educating the public about the benefits and limitations of genomic testing can foster acceptance and participation. 🔍 Ethical Considerations: Addressing ethical issues such as data privacy, consent, and potential discrimination is crucial to maintain public trust and ensure that the benefits of genomic testing are equitably distributed. 📈 Policy and Advocacy: Advocating for policies that promote equitable access to genomic testing and supporting initiatives that aim to reduce disparities in healthcare can drive systemic change. Equitable genomic testing is not just a scientific imperative but a moral one. By working together, we can ensure that the future of medicine is inclusive and beneficial for all. #GenomicTesting #PersonalizedMedicine #HealthcareEquality #DiversityInResearch #InclusiveHealthcare #EthicalScience #HealthcareInnovation #Genomics #HealthEquity #CommunityHealth

Our bodies are like intricate castles, requiring constant vigilance to maintain their strength. That's why I'm excited to share my work on using bioinformatics to identify areas in the human genome linked with high probability to specific illnesses like Alzheimer's and heart disease. Just like a castle guard scans the walls for weaknesses, we can analyze our genomes for potential threats – genetic variants that might increase susceptibility to certain diseases. By monitoring these areas routinely (every 6 months to a year), we can take proactive steps towards prevention, a far better approach than waiting for illness to strike. Imagine a future where: We can identify disease risks early, allowing for preventative measures. Personalized medicine becomes a reality, with treatments tailored to your unique genetic makeup. We empower individuals to take control of their health at the most fundamental level. This is the power of proactive health! #bioinformatics #genomics #preventivehealth #personalizedmedicine #healthcare Exciting Announcement! I'm actively seeking partnerships to further develop this project. Government Health Institutions: If you share our vision for a future of proactive health, I encourage you to reach out to discuss potential sponsorship opportunities. Let's work together to make personalized, preventative healthcare a reality for all. Contact me at [email protected]. Individuals Interested in Personal Gene Cards: While private health institutions often prioritize treatment over prevention, I believe empowered individuals are key to driving positive change in healthcare. If you're interested in learning more about maintaining a personal gene card and monitoring your own health at a genetic level, please feel free to contact me at [email protected] as well. #bioinformatics #genomics #preventivehealth #personalizedmedicine #healthcare

Need more voices from clinic for impact and ecosystem development. Bottom line: “Leveraging technology and data analytics, we can streamline the process of genetic testing and interpretation, ultimately leading to more informed decision-making by healthcare providers”.

The document discusses the national actions being taken in Finland to enable the wider use of genomic data in the Finnish healthcare system. The key actions include: 1. Providing scientific evidence for the utility of genomic information in precision healthcare through pilot studies and health-economic evaluations. 2. Developing a relevant legal framework and infrastructures to enable the responsible and secure processing of genomic data for the benefit of citizens' health and well-being. 3. Building a national multidisciplinary expert network to achieve consensus among stakeholders on issues vital for translating genomic data into precision healthcare. 4. Building competence and genomic literacy skills among healthcare professionals, policy makers, and the general public. 5. Engaging the public to maintain trust and empower citizens in the use of genetic information. These actions aim to establish a roadmap for the expedient application of genomic data in Finnish healthcare and promote the health of citizens. #clinicalgenetics #clinicalgenomics #genomicmedicine #healthcare #humangenetics #medicalgenetics #medicine

🚀 Life Sciences Strategy Development: A Regulatory Framework: 🚀 Our third inquiry session, focusing on the 'Regulatory Framework', featured esteemed speakers including Dr. Keith Ridge and Prof. Ann Lloyd Keen. Insights from industry leaders like Joanne M. Hackett from IQVIA, Seamus Harrison MD PhD FRCS from Genomics plc, Helen Dent from British In Vitro Diagnostics Association (BIVDA), Indra Joshi, and Keith McDonald shed light on genomics' potential and regulatory challenges. https://lnkd.in/gDq5FinN With lessons from COVID-19 and AI's future in healthcare, we're navigating crucial discussions on innovation and risk management. #LifeSciences #RegulatoryFramework #HealthcareInnovation #AI #Genomics #HealthcarePolicy #LSIS #HealthcareInnovation #HealthTech #HealthcareLeadership #HealthcareResearch #LifeSciencesIndustry #HealthcareStrategy #RegulatoryCompliance #HealthcareTechnology #GenomicsResearch #AIinHealthcare #MedicalInnovation #HealthcareInsights

It was a pleasure being part of this discussion and sharing insights #LSIS #RegulatoryFramework #genomics

𝗘𝘂𝗿𝗼𝗽𝗲 𝗗𝗧𝗖 𝗟𝗮𝗯𝗼𝗿𝗮𝘁𝗼𝗿𝘆 𝗧𝗲𝘀𝘁𝗶𝗻𝗴 𝗠𝗮𝗿𝗸𝗲𝘁 𝘁𝗼 𝗯𝗲 𝗪𝗼𝗿𝘁𝗵 $𝟭.𝟱𝟵 𝗕𝗶𝗹𝗹𝗶𝗼𝗻 𝗯𝘆 𝟮𝟬𝟯𝟬 𝗥𝗲𝗾𝘂𝗲𝘀𝘁 𝗳𝗼𝗿 𝗦𝗮𝗺𝗽𝗹𝗲: https://lnkd.in/dhZKWsDJ The Europe direct-to-consumer (DTC) laboratory testing market is anticipated to reach $1.59 billion by 2030, growing at a CAGR of 10.8% from 2024 to 2030. This growth is driven by factors such as the rising incidence of chronic and sexually transmitted diseases, increased awareness about personal health management, and the convenience, affordability, and accessibility offered by DTC testing. Additional drivers include the escalating cost of healthcare, heightened consumer interest in ancestry and genealogy testing, and the aging population. Opportunities for market expansion include the growing adoption of telehealth, the development of emerging economies, and the increased use of pharmacogenomic testing. However, challenges such as concerns over genetic data privacy, potential misinterpretation of test results, and the lack of professional medical counseling pose risks. Market growth is also restrained by issues related to sample integrity, regulatory concerns, limited test portfolios compared to conventional testing, and the lack of reimbursement. 𝗘𝘂𝗿𝗼𝗽𝗲 𝗗𝗧𝗖 𝗟𝗮𝗯𝗼𝗿𝗮𝘁𝗼𝗿𝘆 𝗧𝗲𝘀𝘁𝗶𝗻𝗴 𝗠𝗮𝗿𝗸𝗲𝘁 𝗦𝗲𝗴𝗺𝗲𝗻𝘁𝗮𝘁𝗶𝗼𝗻: *𝗕𝘆 𝗔𝗽𝗽𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻: Genetic Testing, Diabetes Testing, Routine Clinical Testing, Thyroid Function Testing, Sexually Transmitted Disease Testing, Other Applications *𝗕𝘆 𝗦𝗮𝗺𝗽𝗹𝗲 𝗧𝘆𝗽𝗲: Blood, Saliva, Urine, Other Samples *𝗕𝘆 𝗖𝗼𝘂𝗻𝘁𝗿𝘆: U.K., Germany, France, Spain, Italy, Switzerland, Netherlands, Belgium, Denmark, Ireland, Rest of Europe (RoE) *𝗞𝗲𝘆 𝗣𝗹𝗮𝘆𝗲𝗿𝘀: LetsGetChecked, 23andMe, Medichecks, cerascreen, Living DNA, Selfdiagnostics Deutschland GmbH, SYNLAB International, Natrix Srl, Mainz Biomed #DTCTesting #LaboratoryTesting #HealthTech #PersonalHealth #GeneticTesting #HealthAwareness #ChronicDisease #Telehealth #HealthcareInnovation #AncestryTesting #GenealogyTesting #Pharmacogenomics #HealthManagement #ElderlyCare #HealthData #ConsumerHealth #DTCHealthcare #HealthTrends #TestResults #GeneticPrivacy 

Our healthcare ecosystem comprises of diverse stakeholders that seeks to develop and deliver innovative health technologies to maximize the benefits to those in need of care while ensuring sustainability. Understanding the true value of health technologies in decision-making is crucial to ensure that treatments are being delivered efficiently while balancing the incentives for continued innovation of technologies that yield a consumer surplus. Value assessment approaches generate signals of the value of health technologies but can also help us understand the prices we see being paid in the market. Sometimes market participants continue to pay more for a medicine than a conventional CEA would suggest is rational, and yet adding a few petals of the value flower can reveal that the market price is actually cost-effective. Especially when coverage decisions are based on CEAs, whether or not a CEA incorporates a value element may have a real impact on people’s lives. It is therefore imperative that we update our approaches to valuing innovative health technologies with GCEA while acknowledging our continued inability to compute the value of all that we actually value. To comprehensively capture the value of health technologies – both cost and benefits – novel and broader sources of value should be incorporated into cost-effectiveness frameworks. GCEA provides a unified, updated inventory of societal value components and recommends best practice guidance to empirically estimate the total value of medical innovation. This paper aims not only to enumerate and define these value components, but also to explain clearly how these can be estimated in practice. By using the GCEA to incorporate comprehensive societal costs and benefits, researchers and policy makers will be able to better appreciate the value that these medical technologies bring to society. ISPOR—The Professional Society for Health Economics and Outcomes Research International Society for Pharmacoepidemiology #valuebasedcare #valueassessment #marketaccess #heor #healtheconomics #healthcare #pharma #patientjourney #patientcentricity #realworldoutcomes #patientoutcomes #costeffectiveness #ispor #hta #healthtechnologyassessment

🗝️ Can genomics be the key to better public health strategies? Over the last 15 years, we've seen a surge in the use of genetic testing, driven by technological advances and decreasing costs. Governments worldwide have invested over $4 billion in national genomics initiatives, recognising the important role of genomics in improving population health outcomes. Here's my take on the key impacts of genomics on public health policy: Risk and early disease detection: Genetic sequencing enables the identification of individuals at increased risk for conditions such as cancer and cardiovascular diseases. Early detection allows for early intervention and personalised prevention strategies. Population-level screening: Moving from family history-based screening to population-wide genetic testing can uncover at-risk individuals who might otherwise be missed. For example, population-level BRCA screening has been shown to save lives and reduce healthcare costs. Polygenic risk scores (PRS): These scores aggregate the effects of numerous genetic variants to estimate an individual's predisposition to certain diseases. PRS can enhance risk prediction and enable early intervention and personalised treatment plans. Integrating genetic testing into public health strategies requires careful planning, robust infrastructure, and international collaboration. But by doing so, we can significantly improve healthcare outcomes, reduce the burden on healthcare systems, and advance precision public health. ❓Want to learn more about how genomics can inform your public health strategies? Sanogenetics.com has detailed insights and resources – or DM me to discuss! ♻️ Share this post – I'm interested in your opinions!